MYOS Sponsors Sixth Annual Edition Of Scientific American Worldview

CEDAR KNOLLS, NJ--(Marketwired - June 26, 2014) - MYOS Corporation (“MYOS” or the “Company”) (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it is a featured sponsor of the Sixth Annual Edition of Scientific American Worldview (“Worldview”).

The 2014 issue of Scientific American Worldview covers a wide range of global biotechnology topics including the 6th Annual Worldview Scorecard which uses new metrics and its growing pool of data to offer a more balanced assessment of the biotech industry around the world. This year’s issue also focuses on three key topics: biomedical innovation; a comparison on costs of industry research against the value of outcomes; and the limitless opportunities offered from forging partnerships and collaborations.

Peter Levy, MYOS’ President and Chief Operating Officer, commented, “As an emerging leader in muscle health, MYOS is keenly aware of the visibility that a publication such as Worldview offers to multiple stakeholders worldwide. The sixth annual edition captures the thought-provoking conversations of prominent biomedical leaders, including our Chairman, Dr. Robert Hariri, and the cutting-edge multidisciplinary nature of the life sciences industry today. The thought-leaders showcased in Worldview are setting the stage for the future of biotechnology through innovation and MYOS is honored to be included among the sponsors of these groundbreaking visionaries who will undoubtedly have a transformational impact on the future of food, energy and medicine.”

The MYOS sponsored feature Worldview article entitled “Staying Strong” discusses the importance of muscle as it relates to the prevention of sarcopenia, a degenerative loss of lean skeletal muscle mass, quality, and strength associated with aging, which can increase the risk of frailty, physical disability, declining quality of life and potentially death. Researchers believe maintaining lean muscle health plays a central role in the body’s ability to defend itself against age-related disease including cancer, Alzheimer’s and Parkinson’s diseases. Throughout the body’s natural aging process, myostatin protein increases, resulting in the age-associated loss of lean muscle mass. However, various research studies have shown that the regulation or inhibition of myostatin production may be a key component to upholding muscle health and regaining lean muscle mass. As the owner of the first clinically proven myostatin inhibitor, Fortetropin™ (MYO-T12®), MYOS along with other biopharmaceutical innovators is focused on advancing biotherapeutic drug development to deliver safe and effective treatment myostatin regulation options with the ultimate goal of reversing and preventing sarcopenia.

About Scientific American
Scientific American is at the heart of Nature Publishing Group’s consumer media division, meeting the needs of the general public. Founded in 1845, Scientific American is the oldest continuously published magazine in the U.S. and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 14 local language editions around the world it reaches more than 5 million consumers and scientists. Other titles include Scientific American Mind and Spektrum der Wissenschaft in Germany. Scientific American won a 2011 National Magazine Award for General Excellence. For more information, please visit www.scientificamerican.com.

About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™ (MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as “The Muscle Company,"™ visit www.myoscorp.com.

The Company’s first commercial product based on Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ (MYO-T12®) and its effects on myostatin inhibition, including our research and development activities, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.